Loomis, Sayles & Company
EBS icon

Loomis, Sayles & Company’s Emergent Biosolutions EBS Stock Holding History

Loomis, Sayles & Company’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115,054
Closed -$10.7M – 850
2021
Q1 		$10.7M Sell
115,054
-4,088
-3% -$419K 0.01% 379
2020
Q4 		$10.7M Sell
119,142
-396,957
-77% -$36.4M 0.01% 364
2020
Q3 		$53.3M Sell
516,099
-58,401
-10% -$6.3M 0.08% 98
2020
Q2 		$45.4M Buy
574,500
+132,154
+30% +$9.85M 0.07% 104
2020
Q1 		$25.6M Buy
442,346
+263,898
+148% +$15.2M 0.05% 132
2019
Q4 		$9.63M Buy
+178,448
New +$9.68M 0.02% 357
2018
Q4 		– Sell
-168
Closed -$11K – 861
2018
Q3 		$11K Buy
168
+7
+4% +$408 ﹤0.01% 793
2018
Q2 		$8K Sell
161
-18
-10% -$938 ﹤0.01% 825
2018
Q1 		$9K Sell
179
-630
-78% -$31.4K ﹤0.01% 813
2017
Q4 		$38K Sell
809
-62
-7% -$2.61K ﹤0.01% 639
2017
Q3 		$35K Sell
871
-216
-20% -$7.82K ﹤0.01% 658
2017
Q2 		$37K Buy
1,087
+209
+24% +$6.45K ﹤0.01% 639
2017
Q1 		$25K Hold
878
– – ﹤0.01% 739
2016
Q4 		$29K Buy
878
+615
+234% +$18.4K ﹤0.01% 721
2016
Q3 		$8K Hold
263
– – ﹤0.01% 796
2016
Q2 		$7K Sell
263
-810,167
-100% -$31.8M ﹤0.01% 794
2016
Q1 		$29.5M Sell
810,430
-4,765
-0.6% -$168K 0.08% 175
2015
Q4 		$32.6M Sell
815,195
-3,156
-0.4% -$110K 0.09% 160
2015
Q3 		$23.3M Sell
818,351
-844
-0.1% -$27.8K 0.07% 237
2015
Q2 		$27M Buy
819,195
+29,235
+4% +$906K 0.07% 241
2015
Q1 		$22.7M Sell
789,960
-53,910
-6% -$1.55M 0.06% 293
2014
Q4 		$23M Sell
843,870
-42,803
-5% -$1.02M 0.06% 278
2014
Q3 		$18.9M Sell
886,673
-23,442
-3% -$537K 0.06% 341
2014
Q2 		$20.4M Buy
910,115
+53,647
+6% +$1.25M 0.06% 347
2014
Q1 		$21.6M Sell
856,468
-5,804
-0.7% -$147K 0.06% 322
2013
Q4 		$19.8M Sell
862,272
-8,222
-0.9% -$171K 0.06% 359
2013
Q3 		$16.6M Sell
870,494
-4,735
-0.5% -$84.5K 0.05% 397
2013
Q2 		$12.6K Buy
+875,229
New +$12.7M 0.05% 427

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company's EBS Position: Q2 2021 in Review

Loomis, Sayles & Company sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 115,054 shares — an estimated $10.7M sold.

Loomis, Sayles & Company first reported a position in EBS in Q2 2013 and held it in 28 quarters. The position peaked at $53.3M in Q3 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Loomis, Sayles & Company reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 115,054 Emergent Biosolutions shares in Q2 2021, an estimated $10.7M.
  • Loomis, Sayles & Company first reported a position in Emergent Biosolutions in Q2 2013 and held it in 28 quarters.
  • Loomis, Sayles & Company's Emergent Biosolutions position peaked at $53.3M in Q3 2020.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.